Biomarkers of Alzheimer's Disease Among Mexican Americans
Biomarkers of Alzheimer's Disease Among Mexican Americans
复制标题
DOI：
10.3233/jad-122074
复制
发表时间：
2013-01-01
影响因子：
4
通讯作者：
Barber, Robert
中科院分区：
文献类型：
--
作者：
O'Bryant, Sid E.;Xiao, Guanghua;Barber, Robert
背景：墨西哥裔美国人是美国人口中老龄化最快的部分，然而关于这部分人口中阿尔茨海默病（AD）的科学文献很少。现有文献表明，阿尔茨海默病的生物标志物会根据种族/民族而变化，尽管之前没有工作明确研究过这种可能性。本研究的目的是在墨西哥裔美国人中建立一种基于血清的AD生物标志物谱。方法：对德克萨斯州阿尔茨海默病研究与护理联盟（TARCC）的363名墨西哥裔美国参与者（49名AD和314名正常对照）的数据进行分析。非空腹血清样本使用基于luminex的多路复用平台进行分析。使用随机森林分析生成生物标志物概况。结果：在变量重要性图方面，墨西哥裔美国人的AD生物标志物谱与非西班牙裔人群的先前工作不同。事实上，许多顶级标记物与代谢因子有关（如FABP、GLP-1、CD40、胰腺多肽、胰岛素样生长因子和胰岛素）。生物标志物谱是AD状态的重要分类器，在接受者工作特征曲线下的面积，灵敏度和特异性分别为0.77,0.92和0.64。将生物标志物与临床变量相结合可以更好地平衡敏感性和特异性。结论：墨西哥裔美国人AD的生物标志物谱与之前在许多大规模研究中发现的非西班牙裔病例有显著不同。这是第一个明确检查并为墨西哥裔美国人阿尔茨海默病血液生物标志物提供支持的研究。强调了未来的研究领域。
Background: Mexican Americans are the fastest aging segment of the U. S. population, yet little scientific literature exists regarding the Alzheimer's disease (AD) among this segment of the population. The extant literature suggests that biomarkers of AD will vary according to race/ethnicity though no prior work has explicitly studied this possibility. The aim of this study was to create a serum-based biomarker profile of AD among Mexican American.Methods: Data were analyzed from 363 Mexican American participants (49 AD and 314 normal controls) enrolled in the Texas Alzheimer's Research & Care Consortium (TARCC). Non-fasting serum samples were analyzed using a luminex-based multi-plex platform. A biomarker profile was generated using random forest analyses.Results: The biomarker profile of AD among Mexican Americans was different from prior work from non-Hispanic populations with regards to the variable importance plots. In fact, many of the top markers were related to metabolic factors (e. g., FABP, GLP-1, CD40, pancreatic polypeptide, insulin-like-growth factor, and insulin). The biomarker profile was a significant classifier of AD status yielding an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.77, 0.92, and 0.64, respectively. Combining biomarkers with clinical variables yielded a better balance of sensitivity and specificity.Conclusion: The biomarker profile for AD among Mexican American cases is significantly different from that previously identified among non-Hispanic cases from many large-scale studies. This is the first study to explicitly examine and provide support for blood-based biomarkers of AD among Mexican Americans. Areas for future research are highlighted.